Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report sent to investors on Tuesday.

Pulse Biosciences Price Performance

PLSE opened at $18.73 on Tuesday. Pulse Biosciences has a 12 month low of $6.59 and a 12 month high of $22.69. The stock has a fifty day moving average price of $17.99 and a 200-day moving average price of $16.71.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the firm posted ($0.19) earnings per share.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert W. Duggan purchased 56,054 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were purchased at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the purchase, the director now owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. 71.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Franklin Resources Inc. acquired a new position in Pulse Biosciences during the third quarter valued at $378,000. Barclays PLC raised its stake in shares of Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after buying an additional 23,738 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock valued at $8,020,000 after buying an additional 33,200 shares during the period. State Street Corp boosted its stake in shares of Pulse Biosciences by 17.8% in the third quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after buying an additional 69,696 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences during the third quarter worth about $588,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.